Regeneron (REGN) Receives a Hold from J.P. Morgan


In a report issued on April 8, Cory Kasimov from J.P. Morgan maintained a Hold rating on Regeneron (REGN). The company’s shares opened today at $397.18.

According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 1.2% and a 42.2% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Global Blood Therapeutics, and Allogene Therapeutics Inc.

Regeneron has an analyst consensus of Hold, with a price target consensus of $429.38, an 8.1% upside from current levels. In a report issued on April 2, Cantor Fitzgerald also maintained a Hold rating on the stock with a $441 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $442 and a one-year low of $281.89. Currently, Regeneron has an average volume of 667.9K.

Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. Last month, Leonard Schleifer, the President & CEO of REGN bought 100 shares for a total of $2,125.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Read More on REGN:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts